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Abstract The value of nuclear protein (NP) as a prog- 
nostic parameter in prostatic adenocarcinoma w s in- 
vestigated. The NP and DNA contents of two prostatic 
tumour lines with a well-documented hormonal de- 
pendency (PC-82, PC-EW) were compared to the NP 
and DNA contents of two xenografts with only partial 
or no response to androgen deprivation (LNCaP, PC- 
133). After hormonal treatment the PC-82 and PC-EW 
tumours howed a significant decrease in the NP/DNA 
ratio, which coincided with a decrease in the prolif- 
erative activity [anti-bromodeoxyuridine (BRDU) 
antibody-labelling index] of the same specimens. In the 
fast-growing LNCaP tumour an increased percentage 
of cells with high NP and DNA contents was found. 
The tumours PC-82, PC-EW, and PC-133 with lower 
proliferative activity showed lower nuclear protein and 
DNA contents. In a pilot study of 20 prostatic biopsies 
the amount of nuclear protein and DNA in grade 1 3 
tumours as well as in dysplasia was measured. Statist- 
ically significant differences (P < 0.002) were found be- 
tween grade 1 and grade 3 tumours. The mean 
NP/DNA ratio was increased in high-grade 
malignancies. Nuclear protein appeared to be a poten- 
tial parameter in predicting rowth activity in prostatic 
carcinoma. 
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Introduction 
Prostatic adenocarcinoma is a common disease in el- 
derly men. The number of prostatic tumours is increas- 
ing in incidence, due to the rising number of aged men 
and improvements in diagnostic ability to detect his 
malignancy at an early stage. The prevalence of pros- 
tatic carcinoma t autopsy is 30% in the 7th decade of 
life. Only one-third of these prostatic ancers become 
clinically manifest and one in three patients die of the 
disease. The natural history of prostatic arcinoma is
still unpredictable: much depends on tumour stage and 
tumour grade. The aggressiveness of the tumour is 
determined by several factors, including rowth activa- 
tion and genetic instability [19]. 
Disease progression and metastases occur in most 
patients with advanced stage and grade. In metastatic 
disease ndocrine therapy prolongs the time to progres- 
sion. In cases of relapse after adequate ndocrine ther- 
apy, approximately 90% of patients die from their 
disease within 2 years [3, 18]. 
In advanced tumours various degrees of differenti- 
ation are found: well-differentiated tumour cells are 
found next to anaplastic tumour areas. Undifferen- 
tiated tumour cells have lost their potency to respond 
to androgen deprivation and their growth activity is 
responsible for progression towards androgen-inde- 
pendent disease [9]. 
Several tumour markers have been investigated to 
provide better information about tumour behaviour. 
Both the monoclonal antibodies Ki-67 and anti-bro- 
modeoxyuridine (anti-BRDU) were found to be suit- 
able cell proliferation markers, being expressed only in 
cycling and S-phase cells, respectively [12, 13]. In addi- 
tion, nuclear morphometry, DNA ploidy, and image 
cytometry have provided important information about 
tumour behaviour [4, 21J. Using quantitative c ll anal- 
ysis, Auer et al. [-1] determined the proliferative activity 
of lymphocytes by measuring the amount of nuclear 
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protein (NP). Compared to non-cycling cells, a two- to 
threefold increase in total nuclear protein content was 
found in the G1 phase of the cell cycle, which was 
considered an early sign of growth activation. 
In this pilot study we investigated whether nuclear 
protein is a suitable parameter for predicting rowth 
activation in human prostatic arcinoma. 
Materials and methods 
Tumour models 
Four prostatic tumour lines which are permanently transplantable 
in athymic nude mice were used. Table 1 shows estimated tumour 
doubling time in vivo in nude mice and the response to hormonal 
deprivation of the PC-82, PC-EW, PC-133, and LNCaP xenografts. 
The PC-82 tumour line, derived from a moderately differentiated 
human prostatic arcinoma, has high-affinity specific androgen re- 
ceptors and responds to androgen deprivation by growth arrest [61. 
The PC-EW tumour, which is derived from a lymph node metastasis 
of human prostate cancer, consists of moderately and poorly differ- 
entiated tumour tissue. The tumour contains androgen receptors 
and also responds to androgen deprivation [71. The LNCaP tumour 
line, which is aneuploid, was derived from a lymph node metastasis 
of a human prostatic arcinoma. Cultured LNCaP cells were injec- 
ted into athymic mice and subsequently solid tumours developed, of 
which the tissue was serially transplantable [22]. The rate of turnout 
growth of the LNCaP tumour is independent of the hormonal status 
of the host animal [2, 8]. The PC-82 and PC-EW tumours have 
a low growth activity compared to the LNCaP tumour. The PC-133 
tumour is derived from a poorly differentiated human prostatic 
carcinoma, it does not contain androgen receptors and it shows 
androgen-independent growth. 
The number of proliferating cells in the PC-82 and the PC-EW 
tumours was estimated before and after hormonal treatment using 
the anti-BRDU antibody-labelling technique. With respect o nu- 
clear protein as prognostic marker, the hormone-dependent tumour 
models (PC-82, PC EW) were compared to the tumour cell lines with 
only partial response (LNCaP) or no response to androgen depriva- 
tion (PC-133). 
Patient material 
As a pilot study, 20 specimens of human prostatic epithelium were 
investigated with no prior knowledge of the histological diagnosis 
(WHO grading [-111) of the tumour. The NP/DNA ratio of 
50-100 cells per specimen was measured by cytophotometry. Pros- 
tatic carcinoma cells were obtained for cyto-analysis using the 
transrectal spiration biopsies technique as described by Franz~n 
et al. [5]. 
Table 1 Characteristics of four human prostatic turnout lines, per- 
manently transplantable in athymic mice 
Tumour Grade Doubling time Androgen 
(days) dependency 
PC-82 2 18 Dependent 
PC-EW 2/3 10 Dependent 
PC-133 3 10 Independent 
LNCaP 3 5 Partly dependent 
Staining procedure 
The puncture needle was flushed several times in a preservation 
medium containing polyonic in 25% ethanol. The suspension was 
centrifuged (10 minx 25g) and the supernatant was resuspended in 
1 ml Carbowax, centrifuged again and diluted to a cell concentration 
of about 20 000 cells/ml. Slide preparation was performed with 
a 2-ml suspension in buckets for centrifugation at high force 
(15 minx 1250g). The slides were air dried at room temperature and 
stained with acriflavine-Feulgen-SITS (AFS) for DNA and protein. 
Rainbow trout erythrocytes were used for DNA and NP reference. 
The AFS-staining procedure uses acriflavine-Feulgen, which 
quantitatively stains DNA in the nucleus, and stilbene isothyonate 
sulphonic acid (SITS), which is semiquantitatively bound to cellular 
protein [231. This staining procedure has been developed for auto- 
mated cancer screening, but is also suitable for cytomorphological 
interpretation [-20]. The nucleus and the cytoplasm can be sequen- 
tially visualized using the different spectral characteristics of the two 
dyes: acriflavine-Feulgen absorbs blue light with a wavelength of 
466 nm, resulting in a yellow nuclear fluorescent image with clear 
morphological detail, whereas SITS is invisible at this wavelength. 
The SITS image can be visualized using excitation with UV light, 
resulting in a blue fluorescent image of cellular protein. 
The slides were fixed in 100% ethanol for 60 min. After 3 min 
rinsing with distilled water, hydrolysis was performed in HC1 5 N at 
28 ~ for 45 min. Another 3 rain rinsing was followed by staining 
with acriflavine (0.1% at 28 ~ for 30 min. Non-covalently bound 
acriflavine was removed by a solution of 1% HC1 in 70% ethanol. 
Preparations were rinsed with phosphate-buffered solution (PBS) 
for 5 min and citric acid phosphate buffer (pH = 5.5) for 5 min. The 
protein was then stained by SITS in 0.01% citric acid phosphate 
buffer for 15 min. Dehydration was performed in 100% ethanol for 
30 rain. The slides were mounted in Fluoromount (Sigma, St. Louis). 
Nuclear protein and DNA measurements 
Using the appropriate filters (LP 515, KP 490), the fluorescence 
signals were measured sequentially within the nucleus of the cell 
with an MPV microscope fluorometer (Leitz, Germany) [181. The 
nuclear protein and DNA contents of approximately 100 nuclei per 
specimen were measured sequentially. The measurements of abso- 
lute fluorescence signals are hampered by several variable factors, 
including light scatter from the mercury lamp and photoblending of 
the label due to repeated light exposure. Since these factors affect 
both NP and DNA measurements equally, determination of the 
NP/DNA ratio permits comparison of the results of different slides. 
The NP/DNA ratio was determined for each nucleus. The results 
of these measurements were compared with the results of the his- 
tological diagnosis of the same tumour, using the WHO classifica- 
tion for turnout grading [11]. 
Statistics 
Statistical analysis was performed using Wilcoxon's rank sum test 
and Student% t-test, provided by the SPSS/PC computer program 
(SPSS, Chicago). Fifty to 100 items of data per specimen were 
available for statistical analysis. Differences were considered signifi- 
cant at P < 0.05. 
Results 
The nuclear protein and DNA contents of 50-100 tu- 
mour cells per specimen of the four tumour lines were 
measured. Figure 1 shows the NP/DNA profile of the 
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Fig. 1 Histograms of the mean NP/DNA ratio (and standard evi- 
ation) of a PC-82 and b LNCaP tumour lines, growing in untreated 
male mice. a Mean ratio = 2.16; SD = 0.75. b Mean ratio = 3.38; 
SD = 1.69 
PC-82 tumour and the LNCaP tumour. An increasing 
number of cells with high DNA and NP contents are 
observed in the LNCaP tumour. 
The NP/DNA ratio and the percentage of cells with 
high NP and DNA contents of the PC-82 and PC-EW 
tumours were measured before and after androgen 
deprivation and compared to the anti-BRDU anti- 
body-labelling index of the same tumours (Table 2). 
Castration of the nude male mice resulted in a signifi- 
cant decrease in the NP/DNA ratio in both tumours. 
Moreover, the number of cells with high NP and DNA 
contents decreased, comparable to the decrease in the 
anti-BRDU labelling index. The number of cells ex- 
ceeding twice the NP and DNA reference values (rain- 
bow trout erythrocytes) also decreased after androgen 
deprivation (Table 2). The coefficient of variation of the 
mean NP/DNA ratio of the rapidly growing LNCaP 
tumour was statistically different (P < 0.001) from the 
value of the relatively slow-growing PC-82, PC-EW 
and PC-133 tumours (Fig. 1). 
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Table 2 NP/DNA ratio and percentage ofcells with nuclear protein 
and DNA contents exceeding twice the reference value (rainbow 
trout erythrocytes) of four turnout lines of human prostatic aden- 
ocarcinoma, before and after hormonal deprivation. The hormonal- 
dependent tumour lines PC-82 and PC-EW were measured before 
and 30 days after castration of the athymic mouse and the anti- 
BRDU index was determined from the same specimen (Anti-BRD U 
anti-bromodeoxyuridine labelling index, ND not determined) 
NP/DNA % cells exceeding Anti-BRDU 
ratio 2 x NP/2 • DNA index (%) 
PC-82 
Before castration 2.16 13.0 10.0 
After castration 1.14 0 0.6 
PC-EW 
Before castration 2.31 13.3 6.1 
After castration 1.08 1.9 0.8 
PC-133 2.87 9.6 ND 
LNCaP 3.38 10.4 ND 
The mean NP/DNA ratio of 20 specimens of human 
prostatic adenocarcinoma w s compared to the his- 
tological grade of the same tumour (Table 3). Although 
statistically not significant, a tendency towards ahigher 
mean NP/DNA ratio in high-grade malignant 
tumours was observed (P > 0.05). Dysplasia, character- 
ized by an increased mitotic activity, also showed 
a high NP/DNA ratio, due to an increasing number of 
cells with a high nuclear protein content. Figure 2a c 
shows examples of scatterplots ofgrade 1-3 malignant 
specimens. A statistically significant difference was 
found between the grade 1 and grade 3 tumours 
(P < 0.002, Table 3). 
Discussion 
Nuclear protein has been investigated asa parameter of
cell proliferation in human prostatic arcinoma. Cha- 
nges in nuclear protein and DNA content in the differ- 
ent stages of the cell cycle have been described by Roti 
Roti et al. [17] and Pollack et al. [16]. Nuclear protein 
content changed from low values during the GO phase 
to high values in the early G1 phase. A two- to three- 
fold increase in protein was followed by a duplication 
of DNA in the S-phase. The nuclear protein/DNA ratio 
remained high during all phases of the cell cycle (Fig. 3). 
The number of proliferating cells could be determined 
by measuring their nuclear protein content [1, 17]. 
Using the R3327-G rat prostatic arcinoma, Pollack et 
al. [16] showed that the number of cells in the mid-S 
phase was increased after treatment with testosterone. 
Changes in the nuclear protein content appeared to 
proceed a change in tumour volume. The aim of the 
present study was to investigate NP as a potential 
prognostic factor in prostatic carcinoma. From the 
work of Pollack et al. [16], it was concluded that NP 
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Fig. 2 a Example of a scatterplot (NP content versus DNA content) 
of a grade 1 human prostatic adenocarcinoma. Most tumour cells 
have NP and DNA contents comparable to non-cycling cells. 
b Example of a grade 2 tumour. Number of cells with high NP and 
DNA contents is increasing, c Example of a grade 3 tumour. A dis- 
sociation between NP and DNA is observed 
was associated with androgen dependency. Therefore, 
we selected xenograft models with a different response 
to androgen deprivation. From our early results, how- 
ever, it was concluded that NP is related to cell prolifer- 
Table 3 A pilot study of 20 cytological smears of human prostatic 
adenocarcinoma, comparing the mean NP/DNA ratio (range, SD) 
to the histological diagnosis (WHO grading) of the same tumours 
(No. number of specimens~ Ratio mean NP/DNA ratio, SD standard 
deviation) 
No. Ratio Range SD Histology 
1 3.89 0.9-5.4 1.17 Gr 1 
2 4.76 1.3-8.7 1.89 Gr 1 
3 2,97 0.5-6.7 1.54 GR 2 
4 2.00 1.0-5.1 0.82 GR 2 
5 3.74 0.5-7.8 1.92 GR 2 
6 5.27 1.1-10.4 2.35 GR 2 
7 7.45 4.1-14.4 2.78 GR 2 
8 5.46 0.6-11.1 2.84 GR 2 3 
9 6.04 1.3-15.4 3.48 GR 2 3 
10 7.93 1.5-16.7 4.18 GR 2-3 
11 5.10 0.1-10.6 2.42 GR 3 
12 6.05 1.0-11.4 2.92 GR 3 
13 7.26 1.1-11.9 2.44 GR 3 
14 10.52 3.1-17.1 3.10 GR 3 
15 5.05 1.0-9.0 1.80 Dysplasia 
16 6.59 0.1-17.9 4.12 Dysplasia 
17 8.72 4.1-16.7 3.42 Dysplasia 
18 8.77 3.1-14.7 3 .01  Dysplasia 
19 8.79 1.6-18.7 4.43 Dysplasia 
20 9.80 1.3-17.1 5.08 Dysplasia 
NP = high (2 -3x)  
DNA 2c 
G1A G1B 
G 0 - phase 
NP = low )) DNA = 2c S-phase NP = high DNA 2c -> 4c 
ratio < 1.0 
mitosis 
NP = high GII - phase 
DNA = 4c NP = high 
ratio 1.0 -2 .0  DNA = 4c 
Fig. 3 Cell cycle position, nuclear protein content and DNA content 
ation and is not cancer specific. A comparison was 
made to other cell proliferation markers, showing a re- 
markable similarity. 
Two tumour lines (PC-82, PC-EW) with a relatively 
slow growth rate and with well-documented hormonal 
dependency were compared to two tumour lines 
(LNCaP, PC-133) with only partial or no response to 
androgen deprivation in the athymic mouse. The fast- 
growing LNCaP tumour appeared to have a high mean 
NP content, indicating that nuclear protein content 
increases in proliferating tumours. Androgen depriva- 
tion of the PC-82 and PC-EW tumours resulted in 
growth arrest and in a significant decrease in the num- 
ber of proliferating cells (Table 2). This was associated 
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with a significant decrease in the percentage of cells 
exceeding a twofold elevation of the reference NP  and 
DNA contents. 
In a pilot study of biopsy material the amount  of 
nuclear protein in grade 1-3 tumours as well as in 
dysplasia was measured. In spite of the limited number 
of tumours studied, a statistically significant difference 
was found between the grade 1 and grade 3 tumours. 
Dysplastic tissue, characterized by a high number of 
proliferating cells, also showed high NP  contents. The 
mean value of the NP/DNA ratio was increased in 
dedifferentiated tumours, which could be separated 
from the grade 1-2 tumours by estimating the 
NP/DNA ratio. 
To our knowledge there is no other study which has 
measured the same parameters in prostatic arcinoma. 
In two studies of human endometrium, Oud et al. 
[-14, 15] showed that by measuring the NP/DNA ratio 
of isolated nuclei benign and mal ignant cells could be 
separated. Morberger et al. [101 showed that normal 
NP  and DNA characteristics were found in euploid 
endometrial  tumours. Aneuploid tumours, in contrast, 
showed DNA and NP  values indicative of increased 
proliferation activity as well as for a pronounced is- 
order between DNA and NP. 
The outcome of the present study suggests that nu- 
clear protein is a possible parameter  in predicting pro- 
liferative activation in prostatic carcinoma. Since NP  
increases in the very early phase of the cell cycle, it 
might have additional advantages over other prolifer- 
ation markers. Furthermore,  it has been developed as 
a simple technique, suitable for cytophotometry,  auto- 
mated image analysis and flow cytometry. The potency 
of this parameter  is currently being investigated in 
a prospective study. 
References 
1. Auer G, Ono J, Caspersson TO (1983) Determination of the 
fl'action of GO cells in cytological samples by means of 
simultaneous DNA and nuclear protein analyses. Anal Quant 
Cytoi 5:1 
2. Berns EMJJ, de Boer W, Mulder E (1986) Androgen-dependent 
growth regulation of and release of specific protein(s) by the 
androgen receptor containing human prostate tumour cell line 
LNCaP. Prostate 9:247 
3. Byar DP, Corle D (1988) Hormone therapy for prostate cancer: 
results of the Veterans Administration Cooperative Urological 
Research Group studies. In: Consensus Development Confer- 
ence in the Management of Clinically Localized Prostate Can- 
cer, Bethesda. NCI Monogr 7:165 
4. Diamond DA, Berry S J, Jewett H J, Eggleston JC, Coffey DS 
(1982) A new method to assess metastatic potential of 
human prostate cancer: relative nuclear oundness. J Urol 128: 
792 
5. Franz~n S, Giertz G, Zajicek J (1960) Cytological diagnosis of 
prostatic tumours by transrectal aspiration biopsy; a prelimi- 
nary report. Br J Urol 32:193 
6. Hoehn W, Schroeder FH, Riemann JF, Joebsis AC, Hermanek 
P (1980) Human prostatic adenocarcinoma: some character- 
istics of a serially transplantable ine in nude mice (PC 82). 
Prostate 1:95 
7. Hoehn W, Wagner M, Riemann JF, Hermanek P, Williams E, 
Walther R, Schrueffer R (1984) Prostatic adenocarcinoma PC- 
EW, a new human tumor line transplantable in nude mice. 
Prostate 5:445 
8. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, 
Ming Chu T, Mirand EA, Murphy GP (1983) LNCaP model of 
human prostatic arcinoma. Cancer Res 43:1809 
9. Isaacs JT, Heston WDW, Weissman RM, Coffey DS (1978) 
Animal models of the hormone sensitive and insensitive pros- 
tatic adenocarcinoma, Dunning R-3327-H, R-3327-HI, and R- 
3327-AT. Cancer Res 38:4353 
10. Morberger B, Sennerstam R, Auer G (1989) DNA and nuclear 
protein characteristics in non-neoplastic and neoplastic en- 
dometrial tissue. Anal Cell Pathol 2:15 
11. Mostofi FK (1975) Grading of prostatic carcinoma. Cancer 
Chemother Res 59:tl 1 
12. Nemoto R, Uchida K, Shimazui T, Hattori K, Koiso K, Harada 
M (1989) Immunocytochemical demonstration ofS-phase cells 
by anti-bromodeoxyuridine monoclonal antibody in human 
prostate adenocarcinoma. J Urol 141:337 
13. Oomens EHGM, Van Steenbrugge GJ, Van Der Kwast ThT, 
Schr6der FH (1991) Application of the monoclonal antibody 
Ki-67 on prostate biopsies to assess the proliferative cell fraction 
of human prostatic arcinoma. J Urol 145:81 
14. Oud PS, Reubsaet-Veldhnizen JAM, Henderik JBJ, Pahlplatz 
MMM, Hermkens HG, Tas J, James J, Peter Vooijs G (1986) 
DNA and nuclear protein measurement i  isolated nuclei of 
human endometrium, Cytometry 7:318 
15. Oud PS, Reubsaet-Veldhuizen JAM, Beck LM, Pahlplatz 
MMM, Hesslmans GHFM, Hermkens HG, Tas J, James J, 
Peter Vooijs G (1986) DNA and nuclear protein measurement i  
columnar epithelial cells of human endometrium. Cytometry 
7:325 
16. Pollack A, Moulis H, Block NL, Irvin GL (1984) Quantitation 
of cell kinetic responses using simuitaneous flow cytometric 
measurements of DNA and nuclear protein. Cytometry 5:473 
17. Roti Roti JL, Higashikubo R, Blair OC, Uygur N (1982) Cell- 
cycle position and nuclear protein content. Cytometry 3:91 
18. Slack NH, Mittelman A, Brady MF, Murphy GP (1980) The 
importance of the stable category for chemotherapy treatment 
patients with advanced and relapsing prostate cancer. Cancer 
46:2393 
19. Stamey TA, McNeal JE (1992) Adenocarcinoma of the prostate. 
In: Walsh PC, Retik AB, Stamey TA, Vaughan E (eds) 
Campbells urology, voI 2. Saunders, Philadelphia, p 1 I59 
20. Tanke HJ, van Ingen EM, Ploem SJ (1979)Acriflavine-Feulgen- 
stilbene staining: a procedure for automated cervical cytology 
with a television based system (LEYTAS). J Histochem 
Cytochem 27:84 
21. Tribukait B (1987) Flow cytometry in assessing the clinical 
aggressiveness of genito-urinary neoplasms. World J Urol 5:108 
22. Van Steenbrugge GJ, Zhao X, Van Uffelen CJ, Mulder E, 
Schr6der FH (1992) Permanent propagation fthe hmnan pros- 
tatic carcinoma celt line LNCaP in athymic nude mice. Urol Res 
20:436 
23. Wollmer W (1981) Scanning microflurometric measurements of 
acriflavine-Feulgen-SITS stained fibroblasts during G0-G1 
transition. Anal Quant Cytol 3:305 
